



Inhaled drug development: challenges and opportunities

Emelyne Diers

Emelyne Diers, Medicinal Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden

E-mail: emelyne.diers@astrazeneca.com

In 2023, more than 500 million people were affected by chronic respiratory diseases. Reduction in the burden of diseases such as asthma and COPD has progressed considerably. However, significant unmet medical needs persist, driving demand for novel innovative therapies. Oral small molecules and biologics programs prevail in current respiratory drug pipelines. Yet inhalation as a route of administration continues to attract interest for chronic disease treatment given its potential for targeted lung delivery, rapid onset, and reduced systemic exposure. Despite sustained investments by major companies, the development of inhaled modalities remains challenging. This talk aims at exploring the development of inhaled drugs, drawing on both in-house and external data, and will highlight the opportunities ahead for the field.